The Effects of Simvastatin and Bisoprolol Therapy on the Lipids in Serum, Hepatic Biotransformation in Patients with Essential Hypertension and Hypercholesterolaemia Type ll

Abstract

Introduction The aim of the study was to estimate the hypolipemic interaction between simvastatin and bisoprolol during treatment of these drugs the patients with primary mild hypertension and dyslipidemia type II.
Methods The study was undertaken in 43 patients (pts) with arterial hypertension (women: 18, men: 25, age 42-68). Patients were divided in two groups: I group-included 20 pts with basal total cholesterol (TC) > 270 mg/dl and LDL-cholesterol (LDL-C) > 170 mg/dl. After one-month run in period on hypolipemic diet they were treated firstly for 3 months with simvastatin (10-20 mg/daily) after that bisoprolol (5-10 mg/daily) was added for the next 3 months. II group - 23 pts with basal TC between 200 and 270 mg/dl; LDL-C between 130 and 170 mg/dl were given bisoprolol at the same dosage for 3 months. The rate of hepatic metabolism was estimated by antipyrine test.
Results In group I after simvastatin therapy TC and LDL-C levels decreased significant. Added of bisoprolol caused the further significant decreasing of TC and LDL-C. In group II bisoprolol caused nonsignificant decreasing of TC, LDL-C and HDL-cholesterol and increasing of triglicerydes. In both groups we didn't observed significant changes of antipyrine test.
Conclusions Bisoprolol doesn't change the hypolipemic efficacy of simvastatin and it is observed the positive effects therapy simvastatin with bisoprolol on lipids and hepatic biotransformation in patients with hypertension and hypercholesterolaemia type II.